XML 58 R48.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting [Line Items]    
Stock-based compensation expense $ 17,112 $ 8,786
Depreciation expense 39 47
Net loss (92,561) (69,296)
Reportable Segment    
Segment Reporting [Line Items]    
Personnel-related expenses 17,730 13,030
Stock-based compensation expense 17,112 8,786
Depreciation expense 39 47
Other segment expenses 12,089 8,376
Other income, net 13,299 5,432
Net loss (92,561) (69,296)
Reportable Segment | Ulixacaltamide    
Segment Reporting [Line Items]    
Program-specific expenses 19,103 23,513
Reportable Segment | Vormatrigine    
Segment Reporting [Line Items]    
Program-specific expenses 20,494 13,733
Reportable Segment | Relutrigine    
Segment Reporting [Line Items]    
Program-specific expenses 12,854 5,377
Reportable Segment | Elsunersen    
Segment Reporting [Line Items]    
Program-specific expenses 3,197 761
Reportable Segment | Other early stage assets    
Segment Reporting [Line Items]    
Program-specific expenses $ 3,242 $ 1,105